Hardtstock, Fränce
Myers, David
Li, Tracy
Cizova, Diana
Maywald, Ulf
Wilke, Thomas
Griesinger, Frank
Funding for this research was provided by:
Janssen Pharmaceutical Companies of Johnson & Johnson (NA)
Article History
Received: 28 August 2019
Accepted: 12 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: Because of the non-interventional, retrospective nature of analyzed data and because our analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required. However, the study protocol was reviewed and approved by a scientific steering committee to which all the authors belonged. Moreover, the study protocol was reviewed and approved by the sickness fund (AOK PLUS), before access to the data was permitted.
: Not applicable.
: Fränce Hardtstock, Thomas Wilke and Diana Cizova participated in this study as staff members of IPAM; the work of IPAM in this study was financed by Janssen Pharmaceutical Companies of Johnson & Johnson. Thomas Wilke reports honoraria from several pharmaceutical/consultancy companies (Novo Nordisk, Abbvie, Merck, GSK, BMS, LEO Pharma, Astra Zeneca, Bayer, Boehringer Ingelheim, Pharmerit). David Myers and Tracy Li are employees of Janssen Pharmaceutical Companies of Johnson & Johnson. Ulf Maywald is an employee of AOK PLUS and reports Honoria from Roche and MSD. Frank Griesinger participated as a clinical advisor in the Scientific Steering Board. The authors report no other conflicts of interest in this work.